The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy

European Journal of Cancer

Volumn 37, Issue 17, 2001, Pages 2169-2177

  Magne N ^a   Pivot, X ^a   Bensadoun, R J ^a   Guardiola, E ^a   Poissonnet, G ^a   Dassonville, O ^a   Francoual, M ^a   Formento, J L ^a   Demard, F ^a   Schneider, M ^a   Milano, G ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

b.i.d. radiotherapy; Chemo radiotherapy; Epidermal growth factor receptor; Head and neck cancer; Prognostic factor

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GEFITINIB; HEMOGLOBIN; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COBALT THERAPY; CONTROLLED STUDY; FEMALE; GENDER; HEMOGLOBIN DETERMINATION; HUMAN; HYPOPHARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OROPHARYNX CARCINOMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PHARYNGEAL NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0034778619     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00280-5     Document Type: Article

References (40)

1. Head and neck cancer
2. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003
3. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer
4. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma
5. Simultaneous chemo-radiotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study
6. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data
7. Concomitant B.I.D. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: Clinical and pharmacological data of a French multicenter phase II study
8. Systematic percutaneous fluoroscopic gastrostomy for concomitant chemo-radiotherapy of advanced head and neck cancer: Optimization of therapy
9. Prognostic factors for local control, regional control and survival in oropharyngeal squamous cell carcinoma
10. Biological indicators of survival in patients treated by surgery for squamous cell carcinoma of the oral cavity and oropharynx
11. Prognostic value of histological and biological markers in pharyngeal squamous cell carcinoma: A case-control study
12. Characterization, quantification and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas
13. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer
14. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil
15. The clinical evaluation of chemotherapeutics in cancer
16. Epidermal growth factor receptor assay: Validation of a single point method and application to breast cancer
17. Non-parametric estimation for incomplete observations
18. Concomitant cisplatin/5-FU infusion and radiotherapy in advanced head and neck cancer: 8-Year analysis of results
19. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer
20. Prognostic significance of cell kinetics in laryngeal squamous cell carcinoma: Clinicopathological associations
21. Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 in laryngeal cancer
22. Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy
23. P53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma
24. P53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck
25. P53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: A prospective series
26. Quantitative immunohistochemical analysis growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck
27. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival
28. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma
29. Epidermal growth factor-related peptides and their receptors in human malignancies
30. Squamous carcinoma of the head and neck: Cured fraction and median survival time as fuctions of age, sex, histologic type, and node status
31. Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer
32. The impact of nutritional status on the prognoses of patients with advanced head and neck cancer
33. Prognostic value of hemoglobin level for primary radiochemotherapy of head and neck carcinomas
34. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors
35. A comparison of radiotherapy or chemo-radiotherapy with symptomatic treatment alone in patients with advanced head and neck carcinomas
36. Phase I study of chimerized anti-epidermal growth factor recptor (EGFR) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (PTS) with recurrent head and neck and squamous cell carcinoma (SCC)
37. Phase I trial of chimerized anti-epidermal growth factor receptor (anti-EGFR) antibody in combination with either once-daily or twice-daily irradiation for locally advanced head and neck malignancies
38. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
39. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa™), an epidermal growth factor receptor-selective tyrosine kinase inhibitor